Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Waiting, in New Delhi. Photo: Jewel Samad/AFP via Getty Images
While the 95% efficacy rates for the Moderna and Pfizer/BioNTech vaccines are great news for the U.S. and Europe, Monday's announcement from Oxford and AstraZeneca may be far more significant for the rest of the world.
Why it matters: Oxford and AstraZeneca plan to distribute their vaccine at cost (around $3-4 per dose), and have already committed to providing over 1 billion doses to the developing world. The price tags are higher for the Pfizer ($20) and Moderna ($32-37) vaccines.
Details: The Oxford/AstraZeneca vaccine had an average efficacy of 70% in clinical trials, though that rose to 90% under one dosing regimen (patients received a half dose, and then a full dose one month later).
- While that fell short of numbers reported by Moderna and Pfizer, it's well above the 50% efficacy threshold set by the FDA.
The Oxford/AstraZeneca vaccine can also be stored at standard refrigeration levels for six months.
- Moderna's vaccine can be kept under standard refrigeration for 30 days but otherwise must be stored at -20°C
- Pfizer's must be stored at -70°C, a requirement that few developing countries are equipped to handle.
By the numbers: AstraZeneca has already promised 940 million doses to developing countries and another 300 million to the COVAX initiative, according to Duke University's tracker.
- Moderna is also a participant in the COVAX initiative, through which wealthier countries will subsidize access for poorer ones.
- But Moderna's chief medical officer told Axios last week that when it came to COVAX, the company hadn't "quite aligned with them on how many doses and when those doses would be available."
- Pfizer is not a participant in COVAX.
Breaking it down: Pfizer has sold a minimum of 614 million doses to high-income countries and just a combined 14 million in bilateral deals with lower-income countries (Ecuador, Lebanon and Peru), according to Duke's tracker.
- If rich countries exercise their options to buy more of the Pfizer vaccine, they could swallow up nearly all of the 1.3 billion doses the company aims to produce in 2021.
- Moderna has also been selling almost exclusively to rich countries.
- In addition to the 1.24 billion for developing countries, AstraZeneca has sold 1.17 billion doses to rich countries (the U.S., EU, U.K., Japan, Australia and Canada).
The flipside: AstraZeneca will manufacture its vaccine in multiple countries, including India and Brazil, and aims to produce a total of 100 million to 200 million doses per month by the spring.
- Both India (500 million doses) and Brazil (100 million) have secured their access to the vaccine, as have countries including Indonesia (1oo million), Bangladesh (30 million), Egypt (30 million) and Argentina (22 million), according to the Duke tracker.
What to watch: While countries like Canada, the U.S. and the U.K. have hedged their bets by buying enough doses of multiple vaccine candidates to cover their populations several times over, less wealthy countries are cutting deals wherever they can.
- At least 11 countries plan to obtain Russia's vaccine candidate, Sputnik V. The government says the vaccine is 92% effective and has given it partial approval, but has made only limited data available.
- China has also promised several countries access to its vaccine candidates, several of which are in late-stage trials.
Go deeper: Key information about the effective COVID-19 vaccines